Selecta Stock Active With Rights to MMA-101 and AskBio Buyout
While the price surge in shares of Selecta Biosciences (NASDAQ:SELB) receded slightly on October 26 with the stock rising only [...]
SanaCurrents BioTech Back Study Returns Discussed
As you may have read recently or noticed, shares of BioXcel Therapeutics (NASDAQ:BTAI) recorded a 627% gain in seven months [...]
SanaCurrents Following Stock Highs After Coronavirus Developments
Last Friday, the FDA granted emergency use authorization (EUA) to Gilead Sciences, Inc. (NASDAQ:GILD) remdesivir to treat patients hospitalized with [...]
Antibe Pain Relief Drug Catalyst Update
SanaCurrents is closing its position in Antibe this week, due to strong share performance and lack of clarity on key [...]
2019 Winding Down. A Retrospective from SanaCurrents
As 2019 winds to a close, SanaCurrents can look back at mostly good calls and a few disappointments on this [...]
New Approaches to Alzheimer’s After a String of Failures
Did you ever wonder how a company like Biogen, valued at approximately $68 billion earlier this year, could lose one-third [...]
Evolus & Urovant: Similar Strategies, Opposite Reactions to Positive Catalysts
One of the strongest performing biopharmaceutical stocks this year is Evolus (EOLS). When the FDA on February 1 approved the [...]
SanaCurrents Increasing Monthly Sentiment Report Frequency
SanaCurrents is increasing the frequency of its sentiment reports to subscribers to 3 per month. We anticipate there will be a significant [...]